ArticleNMR in biomedicine2026
Metabolomic Relationships Between Lung Cancer and Alzheimer's Disease Using Serum Nuclear Magnetic Resonance Spectroscopy.
Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of serum NMR metabolomics in fibrotic diseases of the myocardium.Metabolomics : Official journal of the Metabolomic Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Lung cancer (LC) and Alzheimer's disease (AD) are both age-associated diseases with high rates of mortality. Studies have reported a possible inverse relationship between LC and AD incidences; however, possible shared molecular mechanisms have not been well investigated. Better characterizations of both diseases and their potential molecular relationships may advance the development of successful therapies for both LC and AD. Metabolomics, as a holistic study of the entire measurable metabolome, has the potential to probe into their metabolic connections. Herein, we used high-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy to study 36 human serum samples collected from primary lung adenocarcinoma patients with or without AD, or AD and related dementia (ADRD). We identified 88 metabolites with 66 metabolites differentiating LC patients from controls, and 80 metabolites discerning LC patients without ADRD from those with ADRD. Our results demonstrate the capability of metabolomics to reveal inversely dysregulated glycolysis, oxidative phosphorylation, and proline metabolism in LC and ADRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.